हिंदी में पढ़ें

Sun Pharma

Sun Pharma drops 5% after US court halts launch of alopecia treatment drug

Sun Pharma drops 5% after US court halts launch of alopecia treatment drug

Mon, Nov 04, 2024

Despite this setback, Sun Pharma’s stock has rallied 43 per cent year-to-date, fueled by growth in speciality drugs, emerging markets, and domestic sales.

Sun Pharma Q2 Results Preview: PAT likely to grow 11.5%; gross margin may improve

Sun Pharma Q2 Results Preview: PAT likely to grow 11.5%; gross margin may improve

Mon, Oct 28, 2024

Led by growth in its domestic business, the specialty generic pharma company is expected to post good July-September quarter.

FINAL TRADE: Sensex ends volatile session down 398 pts, Nifty slides to 24,918 dragged by energy, auto shares

FINAL TRADE: Sensex ends volatile session down 398 pts, Nifty slides to 24,918 dragged by energy, auto shares

Wed, Sep 11, 2024

Share Market News: The Sensex ended 398.1 points lower at 81,523.2 while the Nifty50 settled at 24,918.5, down 122.7 points from its previous close.

TRENDING NOW

Stock of the Day: Today Anil Singhvi gave sell opinion on Tata Steel & Sun Pharma

Stock of the Day: Today Anil Singhvi gave sell opinion on Tata Steel & Sun Pharma

Fri, Aug 02, 2024

Stock of the Day: Today Anil Singhvi gave sell opinion on Tata Steel & Sun Pharma. What is stoploss and targets? See in this video.

Sharekhan picks these 5 stocks for up to 15% gains; check targets and stop losses

Sharekhan picks these 5 stocks for up to 15% gains; check targets and stop losses

Mon, Jul 15, 2024

At 1.51 PM, the Sensex was 0.35 per cent up at 80,799.59 while the Nifty jumped 0.45 per cent to Rs 24,612.40.

Dr Reddy's, Sun Pharma recall drugs in US market: USFDA

Dr Reddy's, Sun Pharma recall drugs in US market: USFDA

Thu, Jul 04, 2024

According to the report, Dr Reddy's Laboratories is recalling drugs to treat insomnia and gout in the American market.

Lupin, Dr Reddy's Labs: 5 pharma stocks CLSA revises stance on

Lupin, Dr Reddy's Labs: 5 pharma stocks CLSA revises stance on

Mon, Jul 01, 2024

As benchmark indices edge higher after beginning the session flat, CLSA has revised its stance on five pharmaceutical stocks. The list includes names such as Dr. Reddy's Laboratories, Lupin, Gland Pharma, and others. Here is a revised list of pharma stocks by the brokerage.

Sun Pharma expects high single-digit top line growth in current fiscal

Sun Pharma expects high single-digit top line growth in current fiscal

Sun, Jun 02, 2024

The Mumbai-based firm reported a consolidated total revenue from operations at Rs 48,497 crore for FY24.

Investor wealth erodes by Rs 5.12 lakh crore in 4-day fall in stock markets

Investor wealth erodes by Rs 5.12 lakh crore in 4-day fall in stock markets

Wed, May 29, 2024

The 30-share BSE Sensex dropped 667.55 points or 0.89 per cent to settle at 74,502.90 on Wednesday. It fell below the 75,000-mark during the day and tanked 715.9 points or 0.95 per cent to 74,454.55.

Should you buy, sell or hold Sun Pharma shares? Here's how analysts view Q4 results

Should you buy, sell or hold Sun Pharma shares? Here's how analysts view Q4 results

Thu, May 23, 2024

Sun Pharma share price target, Sun Pharma Q4 results, Sun Pharma share price NSE: Sun Pharmaceutical Industries shares slipped nearly five per cent on NSE to the day's low of Rs 1,467, a day after the Mumbai-headquartered firm released its March quarter results.

Sun Pharma Q4 Results: Company posts net profit of Rs 2,654.58 crore

Sun Pharma Q4 Results: Company posts net profit of Rs 2,654.58 crore

Wed, May 22, 2024

Consolidated total revenue from operations in the fourth quarter was at Rs 11,982.9 crore in the quarter under review. It was at Rs 10,930.67 crore in the same quarter a year ago, it added.

Sun Pharma Q4 Results Preview: Net profit likely to rise 18% with steady margin

Sun Pharma Q4 Results Preview: Net profit likely to rise 18% with steady margin

Tue, May 21, 2024

Sun Pharma Q4 FY24 Results: Mumbai-headquartered pharmaceutical giant Sun Pharma is all set to report its financial results for the quarter as well as the year ended March 31 on Wednesday, May 22. Analysts expect the drug maker to stage a stable financial performance for the final three mo nths of FY24, with double-digit growth in the domestic business.

Dr Reddy's, Sun Pharma, Aurobindo recall products in US

Dr Reddy's, Sun Pharma, Aurobindo recall products in US

Sun, May 19, 2024

The USFDA said the drug maker initiated the Class I recall in the US on April 8 this year.

Sun Pharma gets Rs 1.11 crore tax demand

Sun Pharma gets Rs 1.11 crore tax demand

Mon, Apr 29, 2024

The company has received an order from the Joint Commissioner, CGST and Central Excise, passed under the GST Act, raising a demand of Rs 1,11,60,156, imposing a penalty of Rs 11,16,016 and interest as applicable, Sun Pharmaceutical Industries said in a regulatory filing.

Sun Pharma's Dadra facility receives OAI inspection status from the USFDA; stock slips

Sun Pharma's Dadra facility receives OAI inspection status from the USFDA; stock slips

Fri, Apr 12, 2024

As of 9:44 a.m., shares of Sun Pharma traded over 1.82 per cent or Rs 29.2, lower at Rs 1574.8 apiece on BSE. The market capitalisation of the company at around the same time stood at Rs 3,77,910.02 crore.

Sun Pharma recalls 55,000 bottles of generic drug from US market due to manufacturing norms violation

Sun Pharma recalls 55,000 bottles of generic drug from US market due to manufacturing norms violation

Sun, Mar 10, 2024

Sun Pharmaceutical Industries Inc is recalling 47,520 bottles (40mg) and 7,488 bottles (80 mg) respectively of the medication due to Current Good Manufacturing Practice regulations (CGMP) deviations, it stated.

Sun Pharma Q3 Results: Net profit rises 16.5% to Rs 2,523.8 crore

Sun Pharma Q3 Results: Net profit rises 16.5% to Rs 2,523.8 crore

Wed, Jan 31, 2024

Sun Pharma Q3 Results: Sun Pharmaceutical Industries Ltd on Wednesday reported a 16.52 per cent rise in its consolidated net profit to Rs 2,523.8 crore in the third quarter ended December 31, 2023.

Sun Pharma Q3 Preview: Firm likely to post healthy set of numbers; gRevlimid sales expected to be around Rs 4.5 crore

Sun Pharma Q3 Preview: Firm likely to post healthy set of numbers; gRevlimid sales expected to be around Rs 4.5 crore

Tue, Jan 30, 2024

Sun Pharma Q3 Preview: Margins are estimated to remain flat at 26.5 per cent against 26.7 per cent registered in Q3 FY23.

Sun Pharma to fully acquire subsidiary Taro Pharma for Rs 2,892 crore; shares rise

Sun Pharma to fully acquire subsidiary Taro Pharma for Rs 2,892 crore; shares rise

Thu, Jan 18, 2024

On Thursday, Sun Pharma shares ended weaker by Rs 14.3, or 1.1 per cent, at Rs 1,299.3 apiece.

Sun Pharma inks pact with Bayer to sell drug for chronic kidney disease

Sun Pharma inks pact with Bayer to sell drug for chronic kidney disease

Wed, Jan 17, 2024

Under the terms of the agreement, Bayer has granted non-exclusive rights to Sun Pharma to market and distribute a second Finerenone product under the brand name Lyvelsa. Finerenone was first launched by Bayer under the brand name Kerendia in 2022.

Sun Pharma Shares Hit 52-Week High Post Acquiring Israel's Libra Merger Ltd | Stock Market News

Sun Pharma Shares Hit 52-Week High Post Acquiring Israel's Libra Merger Ltd | Stock Market News

Wed, Jan 03, 2024

Sun Pharma hits a new high after acquiring Israel's Libra Merger, consolidating its presence in the region. This follows a recent US investment in Lyndra Therapeutics. We break down the deals and their potential impact on Sun Pharma's future.

Sun Pharma, Lupin recall drugs in US market: USFDA

Sun Pharma, Lupin recall drugs in US market: USFDA

Sun, Dec 17, 2023

Mumbai-based Sun Pharmaceutical Industries is recalling 96,192 bottles of Liothyronine Sodium Tablets in the US that are used to treat an underactive thyroid, according to the latest enforcement report issued by the American health regulator.

Sun Pharma revises upwards price to fully acquire Taro to USD 43 per share

Sun Pharma revises upwards price to fully acquire Taro to USD 43 per share

Tue, Dec 12, 2023

Sun Pharmaceutical Industries on Tuesday said it has revised upwards the price at which it proposed to fully acquire Israel-based Taro Pharmaceutical Industries to USD 43 per share in cash.

Load More

LIVE TV

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x